论文部分内容阅读
目的:为了进一步增强重组蛋白质疫苗的细胞免疫应答,利用重组的IL-17作为分子佐剂,与卵清蛋白(ovalbumin,OVA)一起免疫小鼠,研究IL-17作为分子佐剂对适应性免疫的影响,探索IL-17对蛋白疫苗诱导的免疫反应,特别是细胞免疫应答的影响。方法:用OVA作为特异性蛋白疫苗,与不同剂量的IL-17联合免疫C57BL/6小鼠;分别在第0,2周进行免疫,在第3,4周分别检测抗-OVA IgG水平,T淋巴细胞增殖能力,细胞因子表达水平和体内细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)杀伤作用等免疫学指标。结果:以OVA作为的蛋白疫苗在IL-17作为佐剂情况下能够增强抗原特异性的免疫反应,尤其是有效提高细胞免疫应答水平。与单注射OVA蛋白组相比,不同剂量的IL-17不仅增强了OVA特异性抗体水平,而且均能够增强CD 4+T和CD 8+T细胞分泌IL-17的能力,尤其对CD 8+T细胞分泌IFN-γ的表达水平和体内CTL的效果增加明显。结论:IL-17作为蛋白质疫苗的分子佐剂能够增强抗体水平,特异性CD8+T细胞活性,尤其是增强体内特异性的CTL反应,这为增强蛋白质疫苗的特异性细胞免疫反应提供了一个新方法。
OBJECTIVE: To further enhance the cellular immune response of recombinant protein vaccines, mice were immunized with recombinant ovalbumin (OVA) using recombinant IL-17 as a molecular adjuvant to study the effect of IL-17 as a molecular adjuvant on adaptive immunity To explore the impact of IL-17 on protein vaccines-induced immune response, especially cellular immune response. Methods: C57BL / 6 mice were immunized with OVA as a specific protein vaccine at different doses of IL-17. Immunization was performed at weeks 0 and 2, and anti-OVA IgG levels were detected at week 3 and 4 respectively. T Lymphocyte proliferation, cytokine expression and cytotoxic T lymphocyte (CTL) cytotoxicity and other immunological indicators. RESULTS: The OVA-based protein vaccine enhanced antigen-specific immune responses with IL-17 as an adjuvant, especially effective in raising the cellular immune response. Different doses of IL-17 not only enhanced OVA-specific antibody levels, but also enhanced the ability of CD 4 + T and CD 8 + T cells to secrete IL-17, especially for CD 8+ T cell secretion of IFN-γ expression levels and in vivo CTL effect increased significantly. CONCLUSIONS: IL-17, as a molecular adjuvant to protein vaccines, enhances antibody levels, specific CD8 + T cell activity, and in particular enhances in vivo specific CTL responses, providing a novel approach to enhance the specific cellular immune response to protein vaccines method.